Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?
|
|
- Mae Chandler
- 6 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2004; 20 (Suppl. 2): Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research, Nottingham University, University Hospital, Nottingham, UK SUMMARY Non-steroidal anti-inflammatory drugs (NSAIDs) are the major recognized cause of iatrogenic disease, and may cause deaths per annum through peptic ulcer complications. A number of risk factors can be identified that indicate patients at high risk. These patients can be managed by substitution of a COX-2 inhibitor or by prophylaxis with a proton pump inhibitor (PPI). Because risk factors that render patients at high risk of ulcer complications also act in the absence of NSAID use, PPI prophylaxis (or Helicobacter pylori eradication where H. pylori is the risk factor) have much to offer and controlled studies show that the incidence of recurrent peptic ulcer bleeding can be reduced substantially by PPI co-administration. Substitution of COX-2 inhibitors also has much to offer, arguably most in those without risk factors (although regulatory authorities do not accept this argument). Recent data show that PPI and COX-2 inhibitors can play complementary roles in the management of patients with moderate to severe dyspepsia and at high risk of ulcer complications. THE PROBLEM Non-steroidal anti-inflammatory drugs (NSAIDs) are a well-recognized cause of iatrogenic disease, principally because of their ability to cause gastro-duodenal ulcers and complications. 1 These cause significant morbidity and mortality, although some estimates of extent are unrealistically high. 1 Thus the often-quoted rate of deaths to NSAID-associated peptic ulcer complications per annum in the USA 2 seems unlikely, representing as it does 110% of all registered peptic ulcer deaths. Realistic estimates from the UK suggest that about 1000 patients per annum die from the effects of NSAID or aspirin (including low-dose aspirin). 3 Because NSAID are used Correspondence to: Professor C. J. Hawkey, Professor of Gastroenterology, Wolfson Digestive Diseases Centre, Institute of Clinical Research, Nottingham University, University Hospital, Nottingham NG7 2UH, UK. cj.hawkey@nottingham.ac.uk widely it is possible that these figures could imply deaths per annum worldwide. While dyspepsia seems less serious than ulcer bleeding or perforation, it is more common. An estimated 15% of patients are unable to take NSAID because of dyspepsia and a prevalence of (presumably lower level) dyspepsia among chronic users is in the range of 10 25%, representing an approximate doubling compared to non-users. 4 Thrombotic complications of cardiovascular disease In theory NSAID could increase, have no effect on or reduce the incidence of cardiovascular thrombosis via inhibition of prostacyclin, thromboxane or both. In practice there is little effect of NSAID as a group (see Ó 2004 Blackwell Publishing Ltd 59
2 60 C. J. HAWKEY below), 5 although some studies suggest that naproxen, by exerting a profound and prolonged inhibition of platelet thromboxane, might mimic the effects of aspirin and reduce the incidence of myocardial infarction. In the VIGOR study patients on naproxen had fewer thrombotic events than those on rofecoxib. 6 At present it is still unclear whether this represents an antithrombotic effect of naproxen, a prothrombotic effect of selective COX-2 inhibition or a combination of the two. 7 Other side-effects Recently, there has been increasing recognition of the effects of NSAIDs on renal function and of the ability of both NSAIDs and selective COX-2 inhibitors to cause elevation of blood pressure. 7 9 If untreated it is possible that this might ultimately provoke as many cardiovascular events as gastrointestinal events. 3 As noted above, direct study of the effects of NSAID on myocardial infarction has not suggested an overall increase. However, hypertension might influence myocardial infarction only after a prolonged period and the relationship between duration of NSAID use and myocardial infarction has not been investigated systematically. Whether patients on NSAID have an increased instance of stroke is not clear, but two studies have shown that heart failure is more common. MECHANISMS Gastro duodenal ulcers Human and animal data support a notion that there are two main components to NSAID ulcer development. Inhibition of prostaglandin synthesis leads to development of micro-erosions early on. 10 These then become evident erosions and deepen to form peptic ulcers. Acid suppression can diminish progression to erosions and ulcers, but only if intragastric ph is maintained at a relatively high level, typically over Human studies support this notion in that normal doses of proton pump inhibitors (PPIs) or supratherapeutic doses of H 2 antagonists reduce development of gastric ulcers in contrast to normal doses of H 2 antagonists, which do not Much NSAID dyspepsia is responsive to acid suppression. There appears to be a high level of gastro-oesophageal reflux, although how NSAIDs could predispose to this is not clear. Similarly, mechanisms underlying nerve sensitization are somewhat cryptic, given that inhibition of prostaglandin synthesis reduces, rather than increases, pain in other situations. ASSESSING STRATEGIES There is controversy about how strategies to prevent NSAID associated GI side effects should be assessed. A rather simplistic argument about studying ÔrealÕ ulcers has led some regulatory authorities to demand ÔoutcomesÕ studies of Ôclinically significant eventsõ, based on a mistrust of endoscopic surrogates. As detailed below, outcomes studies have disadvantages as well as advantages. 15 Outcomes studies In these studies, a large number of patients (up to ) are studied on drug comparison and the rate of the development of clinically significant events is measured. 6, An apparent advantage of this approach is that an unselected population is studied, making widespread generalization reasonable. However, the life expectancy seen in such studies without active treatment is lower than would be expected for the age group studied, suggesting that fitter-than-average patients are studied and or that the drugs used prolong life (for which there is no supportive evidence). The fact that these trials attempt to study unselected patients and if anything select those with a good outlook actually means that relatively few of the patients that concern regulatory authorities are studied, meaning that their decisions are often not evidence-based. There are several other difficulties with outcome studies. They are incredibly large and expensive to run and because endpoints are relatively rare they are easy to underpower. This may have contributed to the failure of at least one study (CLASS) to achieve a statistically significant endpoint. 19 Moreover, the appealing logic of studying Ôreal clinical eventsõ is more apparent than real. Because of the numbers involved, successful studies have settled for an endpoint described as PUBS (perforations, ulcers and bleeds). The majority of these are uncomplicated ulcers and consequently their incidence maybe confounded by differences in the instance of dyspepsia. Another disadvantage of outcome studies is not only that soft endpoints are used but endpoint
3 WHO SHOULD RECEIVE NSAIDS? 61 assessment is imprecise, because it is not carried out according to protocol and monitoring committees have to make a judgement about imperfectly reported endpoints. Of the two outcome studies of COX-2 inhibitors, CLASS failed to show a statistical significant difference between celecoxib and non-selective NSAIDs, at least in part because of inadequate size. VIGOR, the study of rofecoxib, showed a reduction of 50 60% in selected endpoints compared to naproxen. This fell short of the 75% reduction that might have been expected from epidemiological and endoscopic studies, if rofecoxib were equivalent to placebo in its effects on the development of ulcers and their complications. Whether this is a real difference and, if so, whether it reflects inadequacies of outcomes or endoscopic studies is not known. A recent outcome study of lumiracoxib has studied patients with ulcer complications as its primary endpoint and it will be interesting to see. Whether this larger and arguably more precise study finds bigger differences. Rightly or wrongly, regulatory authorities are not prepared to recommend safer strategies such as the use of COX-2 inhibitors or PPI prophylaxis in low-risk groups, even though it can be argued that this may, in fact, represent the most appropriate target for use of COX-2 inhibitors when indirect costs are taken into account. 3 Given this situation, conventional outcome studies thus study a large number of patients containing a relatively small proportion of those for whom safer prescribing is considered appropriate. Moreover, residual risk when high-risk patients take selective COX-2 inhibitors vs. non-selective NSAIDs remains high. 20 This is not surprising, given that most factors that render patients using non-selective NSAIDs at high risk are risk factors even in the absence of NSAID use. In the VIGOR study there were high levels of residual risk in patients with a past history of ulcer disease vs. those without, and in those infected with H. pylori vs. those who were H. pylori-negative. 7 Recurrence of ulcers and ulcer complications The limitations of selective COX-2 inhibitors, and of conventional outcome studies mentioned above, suggest that a different treatment for high-risk patients and a different approach to its assessment may be more appropriate. PPIs have been studied using a different type of outcomes study (although the term is not applied conventionally in these circumstances). In this approach, patients who present to hospital with a life-threatening ulcer complication (principally ulcer bleeding) are entered into a trial of treatment designed to prevent recurrence over the next 6 months. The merit of this approach is that high-risk patients who are pragmatically a target of prophylaxis are studied. However, because mechanisms may differ, data may not generalize to the whole population. This approach has been applied both to PPIs 2, 21 and COX-2 inhibitors. 23 With PPIs, two studies have investigated such secondary prophylaxis in patients hospitalized initially because of an NSAID-associated bleeding gastric ulcer. In patients continuing to take NSAIDs, PPI prophylaxis reduced 4-fold the risk of a further similar episode over the next 6 months, compared to a strategy of H. pylori eradication. A third study has compared directly a PPI prophylaxis strategy in this group with a switch to COX-2 inhibitors. 23 Results were similar in each group. However, a strategy of H. pylori eradication may have enhanced the effectiveness of COX-2 inhibitors and diminished the effectiveness of PPIs. For aspirin, data are less clear cut. 24 One study showed a very low rate of recurrent problems with H. pylori eradication alone (there was no non-eradication group to determine whether this was a beneficial consequence of eradication 21 ). This low rate made it impossible to determine whether PPIs were effective. In a second study there was a higher rate of recurrent ulcer complications (although in some patients this was associated with failed eradication 22 ). There was a very substantial and significant fall in ulcer complications with PPIs. Medium duration patient endoscopy studies Endoscopy has been used traditionally to evaluate therapeutic strategies for ulcers that are not associated with NSAIDs. There are no good reasons to believe that endoscopy studies are any less valid in patients taking NSAIDs than they are in patients with ulcers who do not. It may be that traditional outcome studies are of no additional value, because their results can be predicted from patient endoscopy studies. 1 Moderately large endoscopy studies in patients over 6 weeks to 6 months have shown a 3- to 4-fold reduction in the development of ulcers with PPI prophylaxis or with switching to a COX-2 inhibitor. 1, 3
4 62 C. J. HAWKEY Interestingly, these are larger differences than are seen in outcome studies. Whether endoscopy studies overestimate the reduction in risk, or outcome studies (because of endpoint imprecision) underestimate it, are interesting questions for which answers have not yet been forthcoming. 25 The Therapeutic Arthritis Research into Gastrointestinal Endpoint Trial (TARGET) by contrast found a five fold difference in ulcer complications (defined in ways that were as close as possible to those used in clinical practice) between lumiracoxib and the NSAIDs naproxen and ibuprofen. Whether this reflects chance, endpoints selections, trial design or drug choice remains to be seen. Short-term volunteer studies These are even less popular as a means of evaluating strategies than are medium-term patient endoscopy studies. 1 Erosions are often declared to be of no clinical significance, although it is not self-evident that they have less significance than ulcers detected endoscopically (with which they are often confused). In fact, erosions are of intrinsic significance in clinical practice, as few would discount their importance when discovered as the sole lesion in patients presenting with a haematemesis. Moreover, as evidence has accrued it has become clear that erosions are strongly predictive in individual patients at risk and in populations of the effectiveness-of-the-individual strategies. 1 Thus, in a study of 1506 patients undergoing endoscopy prior to a study of rofecoxib vs. NSAID over 6 months, those who had erosions at baseline were approximately five times more likely to develop an ulcer in the study. 26 Perhaps even more significantly, they were five times more likely to develop a spontaneous PUB than those without erosions. This influence was stronger than being infected with H. pylori. Moreover, strategies developed from the acute study of erosions in volunteers have been, without exception, predictive of results in patient endoscopy and outcome studies. For example, volunteer studies predicted correctly that only PPIs or high doses of H 2 antagonists would prevent NSAID-associated gastric ulcers, that misoprostol would be effective protection, that use of COX-2 inhibitors would reduce ulcer disease and that any effects of NO donating NSAID would be limited. 1, 3 PRACTICAL PRESCRIBING Reducing ulcer risk COX-2 inhibitor substitution or PPI prophylaxis are normally considered for patients who at increased risk of ulcer complication. While superficially attractive, this preconception needs careful analysis. In general, risk factors that render patients at increased risk of ulcer complications on NSAIDs also render them at increased risk of ulcer complications of NSAIDs. 3 In those with no identifiable risk factors other than the drug, switching to a COX-2 inhibitor results in an extremely low incidence of ulcers and their complications. Thus, in the VIGOR study, patients without other risk factors has an annualized PUB rate of 1.9 per 100 patient-years on NSAIDs and 0.2 per 100-patient years on rofecoxib, a fall of 1.7 event per 100 patient-years. 20 For patients with risk factors the comparable rates were 4.6, 2.1 and 2.5. In some groups such as those with a previous ulcer complication the residual rate on rofecoxib was even higher (approximately 10 events per 100 patientyears 20 ), although small numbers means that there are wide confidence intervals around this estimate. However, broadly speaking the results of CLASS were very similar. Thus, for patients with risk factors, conceptual analysis and experimental evidence suggest that other strategies such as PPI prophylactics or H. pylori eradication should be used as an alternative. ÔÕ is a word used to describe different symptoms with resulting confusion. This is particularly true with NSAID dyspepsia. There is some evidence that patients with NSAIDs have an increased incidence of dismotility, such as dyspepsia with upper abdominal bloating, as well as ulcer-like dyspepsia and reflux-like dyspepsia. How NSAIDs enhance the risk of reflux and of oesophagitis is unknown, but these symptoms seem to be very common. Acid-suppressing drugs such as PPIs and H 2 antagonists have been shown to reduce NSAID dyspepsia, probably via an effect on both ulcerlike and reflux-like dyspepsia. It is probably true that two scenarios characterize NSAID users: the patient who develops severe and disabling dyspepsia early in use, and then discontinues them. Although it has not been studied formally, a treatment that controls dyspepsia and enables continued use would be very helpful in facilitating analgesic
5 WHO SHOULD RECEIVE NSAIDS? 63 and anti-inflammatory benefits. Some anecdotal evidence suggests that this can be achieved with acid suppression. Other patients who continue to take NSAIDs also suffer from dyspepsia at a lower level and in an intermittent way. The intermittency of dyspepsia in NSAID users made the study difficult, in giving an apparently high placebo rate. Nevertheless, recent large systematic trials have shown formally that PPIs such as esomeprazole both reduce NSAID dyspepsia with acute treatment and prevent or retard its return with 27, 28 maintenance. CONCLUSIONS Contrary to the pronouncements of advisory and regulatory bodies, the group with the most to gain from switching to a COX-2 inhibitor may be those without risk factors placing them at high risk of ulcer disease. For many of the latter, co-prescription of a PPI may have advantages over use of COX-2 inhibitors alone in dealing with both drug-related and drugunrelated risk. REFERENCES COMBINED USE OF COX-2 INHIBITORS AND PPIS Reducing ulcer risk NSAID ulcers develop because of aggravation of prostaglandin-mediated mucosal events followed by acid peptic attack. This dual pathogenesis implies a possible benefit from a dual therapy. Recently data with the PPI esomeprazole have suggested that this could be the most effective way to approach the goal of eliminating NSAID-associated ulcers. Ulcer-free patients who were nevertheless at high risk because of age or past history and who were taking either non-selective NSAID or a selective COX-2 inhibitor were randomized to received esomeprazole 20 mg, esomeprazole 40 mg or placebos, and following for up to 6 months. Esomeprazole reduced ulcer development in patients taking NSAID and also did so at least as well in those taking COX-2 inhibitors. 29 Conversely, with past history and continuing H. pylori infection residual rates are substantial, implying a policy of H. pylori eradication and or the alternative of PPI prophylaxis. The latter is also appropriate for patients taking aspirin alone or with NSAID or COX-2 inhibitors. Interestingly, in analogous studies of patients with dyspepsia, esomeprazole also reduced dyspepsia associated with NSAID and in those using COX-2 inhibitors to a similar extent, and this continued with maintenance treatment for up to 6 months. 27, 28 More data are needed but the consistency of these results, together with their biological plausibility, mean that use of selective COX-2 inhibitors and PPIs may be the most effective approach to patients with risk factors for ulcer disease or with disabling NSAID dyspepsia. 1 Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: Singh G. Recent considerations in non-steroidal antiinflammatory drug gastropathy. Am J Med 1998; 105: Hawkey CJ, Langman MJS. Non-steroidal anti-inflammatory drugs. overall risks and management. Complementary roles for COX-2 inhibitors and PPIs. Gut 2003; 52: Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: indigestion and non-steroidal anti-inflammatory drugs. BMJ 2001; 323: Dalen JE. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial infarction. Arch Intern Med 2002; 162: Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2003; 343: Konstam MA, Weit MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: Johnson AG, Nguyen TV, Day RO. Do non-steroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: Whittle BJR. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981; 80: Elliot SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal ph. Clin Exp Pharmacol Physiol 2001; 23: Daneshmend TK, Pritchard PH, Bhaskar NK, Millns P, Hawkey CJ. Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine. Gastroenterology 1989; 97: Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996; 334:
6 64 C. J. HAWKEY 14 Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: Hawkey CJ. Outcomes studies of drug induced ulcer complications: do we need them and how should they be done? BMJ 2000; 321: Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal antiinflammatory drugs. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 1995; 123: Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Longterm Arthritis Safety Study. J Am Med Assoc 2000; 284: Hawkey CJ, et al. TARGET. Lancet. 2004; in press. 19 Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2003; 342: Laine L, Hawkey CJ, Bombardier C, et al.stratifying the risk of clinical upper GI events in NSAID users: results from a double-blind outcomes study [Abstract]. Gastroenterol 2001; Suppl 5: A Chan FKL, Chung SCS, Suen RN, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: Lai KC, Lam SL, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: Francis KL, Chan MD, Lawrence CT, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: Lai K-C, Lam S-K, Chu K-M, et al.h. pylori eradication vs combined PPI and H. pylori eradication in the prevention of recurrent peptic ulcer complications in high-risk patients receiving low-dose aspirin [Abstract]. Gastroenterology 2001; 120 (Suppl. 5): A Hudson N, Everitt S, Hawkey CJ. Inter-observer variability in assessment of gastric lesions by video endoscopy. Gut 1994; 35: Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Alimentary Pharmacol Ther 2001; 15: Hawkey CJ, Yeomans ND, Jones R, et al.esomeprazole improves quality of life in patients with upper GI symptoms associated with long-term NSAID therapy [Abstract]. Gastroenterology 2003; 124 (Suppl. 1): A Yeomans ND, Hawkey CJ, Jones R, et al. Esomeprazole provides effective control of NSAID-associated upper GI symptoms in patients continuing to take NSAIDs [Abstract]. Gastroenterology 2003; 124 (Suppl. 1): A Hawkey CJ, Scheiman J, Yeomans N, et al. Esomeprazole reduces gastric and duodenal ulcer development among high risk NSAID users [Abstract]. Gut 2003; 52 (Suppl. 1): A16.
Gastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationIs ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?
ORIGINAL PAPER doi: 10.1111/j.1742-1241.2006.01147.x Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? N. D. YEOMANS, 1 *L-ESVEDBERG,
More informationNon-steroidal anti-inflammatory drugs and gastrointestinal damage problems and solutions
82 University of Glasgow and Department of Gastroenterology, Royal Infirmary, Glasgow Correspondence to: Professor R I Russell, 28 Ralston Road, Bearsden, Glasgow G61 3BA rirla@aol.com Submitted 26 October
More informationEffective management of gastrointestinal PROCEEDINGS EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS *
EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS * David A. Peura, MD, FACP, FACG ABSTRACT *This article is based on a presentation given by Dr Peura at the PRI-MED
More informationThink Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks
NEWS AND PERSPECTIVES Think Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks Jyh-Ming Liou, 1,2 Ming-Shiang Wu, 1 * Jaw-Town Lin 1,3 Nonsteroidal
More informationSPECIAL REPORT. Aspirin and Risk of Gastroduodenal Complications
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:725 735 SPECIAL REPORT Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions
More informationNSAID-Induced Gastrointestinal Damage
GASTROENTEROLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Gastroenterology Board Review Manual is a study guide for fellows and practicing physicians preparing for board
More informationProtection of human gastric mucosa against aspirinðenteric coating or dose reduction?
Aliment Pharmacol Ther 1999; 13: 187±193. Protection of human gastric mucosa against aspirinðenteric coating or dose reduction? A. T. COLE*, N. HUDSON*, L. C. W. LIEW*, F. E. MURRAY*, C. J. HAWKEY* & S.
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationCARDIOVASCULAR RISK and NSAIDs
CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence
More informationEfficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
Alimentary Pharmacology & Therapeutics Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs C. J. HAWKEY*,
More informationNon-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
600 REVIEW Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors C J Hawkey, MJSLangman... Non-steroidal anti-inflammatory
More informationEvidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1156 1163 REVIEW Evidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm ANDREW MOORE,* INGVAR
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationPrevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best?
Prevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best? Shaden Salamae MD a, Meir Antopolsky MD a, Ruth Stalnikowicz MD a * Department of Emergency Medicine, Hadassah University
More informationManagement of nonsteroidal anti-inflammatory drug
BYRON CRYER, MD ABSTRACT OBJECTIVE: To describe risk factors and review appropriate management strategies for patients who experience nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal
More informationA Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury
A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury A. Mark Fendrick, MD Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed often in the U.S., particularly
More informationAssessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology36-5251Blackwell Publishing 23? 23562146155Original ArticleNSAID damage in the human gastrointestinal tractm. W. James & C. J.
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationPrevalence of gastroduodenal lesions in chronic nonsteroidal anti-inflammatory drug users presenting with dyspepsia at the Kenyatta National Hospital
Research Article Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya Corresponding author: Dr. G O Oyoo. Email: geomondi@hotmail. com Prevalence of gastroduodenal lesions in
More informationProton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs
ORIGINAL ARTICLE Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs Yuki Sakamoto, Tadashi Shimoyama, Satoru Nakagawa,
More informationCelecoxib: the need to know for safe prescribing
medicine indications pain management rheumatology Celecoxib: the need to know for safe prescribing Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor that has been fully subsidised without restriction,
More informationDisclosure. Learning Objectives 1/17/2018. Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with NSAID Use
Disclosure Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with Liz Van Dril, PharmD, BCPS PGY2 Ambulatory Care Resident January 17 th, 2018 Dr. Liz Van Dril has no actual or potential
More informationWhat is Bandolier? Balance benefits and harms
What is Bandolier? The first issue of Bandolier, an independent journal about evidence-based healthcare, written by Oxford scientists, (RAM AND HJM) was printed in February 1994. It has appeared monthly
More informationCharacteristics of selective and non-selective NSAID use in Scotland
Characteristics of selective and non-selective NSAID use in Scotland Alford KMG 1, Simpson C 1, Williams D 2 1 Department of General Practice & Primary Care, The University of Aberdeen. 2 Department of
More informationDyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac
Aliment Pharmacol Ther 2002; 16: 819 827. Dyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac J. L. GOLDSTEIN*, G. M. EISEN, T. A. BURKEà, B. M. PEÑA, J. LEFKOWITH
More informationThe management of arthritis and chronic pain syndromes
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1337 1345 Impact of Adherence to Concomitant Gastroprotective Therapy on Nonsteroidal-Related Gastroduodenal Ulcer Complications JAY L. GOLDSTEIN,* KIMBERLY
More informationEffective Health Care Program
Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis
More informationThe New England Journal of Medicine
VERSUS AND IN REDUCING THE RISK OF RECURRENT ULCER BLEEDING IN PATIENTS WITH ARTHRITIS FRANCIS K.L. CHAN, M.D., LAWRENCE C.T. HUNG, M.D., BING Y. SUEN, R.N., JUSTIN C.Y. WU, M.D., KENNETH C. LEE, PH.D.,
More informationA study on clinical profile and risk factors in drug induced UGI bleeding
Original Research Article A study on clinical profile and risk factors in drug induced UGI bleeding S. Appandraj 1*, V. Sakthivadivel 2 1,2 Associate Professor, Dept. of General Medicine, Karpaga Vinayaga
More informationTECHNOLOGY OVERVIEW. Issue 6 February Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis
TECHNOLOGY OVERVIEW Issue 6 February 2002 Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis Publications can be requested from: CCOHTA 110-955 Green
More informationReview Article. Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) Safety Profile of NSAID
Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) R. Stoilov: University Hospital St Ivan Rilski, Clinic of Rheumatology Contact: Rumen Stoilov, Clinic of Rheumatology, University Hospital St
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More information(i) Is there a registered protocol for this IPD meta-analysis? Please clarify.
Reviewer: 4 Additional Questions: Please enter your name: Stefanos Bonovas Job Title: Researcher Institution: Humanitas Clinical and Research Institute, Milan, Italy Comments: The authors report the results
More informationNonsteroidal anti-inflammatory drugs (NSAIDs),
GASTROENTEROLOGY 2001;120:594 606 Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient LOREN LAINE University of Southern California School of Medicine, Los Angeles, California
More informationPATTERN OF USE OF GASTROPROTECTIVE AGENTS ALONG WITH THE ANTI INFLAMMATORY AND ANALGESICS DRUGS
PATTERN OF USE OF GASTROPROTECTIVE AGENTS ALONG WITH THE ANTI INFLAMMATORY AND ANALGESICS DRUGS K. B. Sanalkumar 1, K. T. Shenoy 2, K. Arun 3, Hema Ilavarasi K. M 4, Venugopalan P.G 5, Leena K. B 6 1Additional
More informationAm J Gastroenterol 2010;105:
ACCF/ACG/AHA 2010 Expert Consensus Document Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document
More informationTechnology Report. Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Antiinflammatory
Technology Report Issue 38 September 2003 Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Antiinflammatory Drugs: A Systematic Review of Preventive Pharmacological Interventions Publications
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationEnhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine
Br. J. clin. Pharmac. (1989), 28, 581-585 Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine G. K. KITCHINGMAN, P. J. PRICHARD, T. K. DANESHMEND,
More informationVimovo (delayed-release enteric-coated naproxen with esomeprazole)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release
More informationThe long-term management of patients with bleeding duodenal ulcers
Aliment Pharmacol Ther (1997); 11: 505±510. The long-term management of patients with bleeding duodenal ulcers M. E. MCALINDON, J. S. W. TAYLOR & S. D. RYDER Department of Medicine, University Hospital,
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationINTRODUCTION ORIGINAL ARTICLE. Sang Gyun Kim 1, Nayoung Kim 2, Sung Kwan Shin 3, In Kyung Sung 4, Su Jin Hong 5 and Hyo-Jin Park 3
ORIGINAL ARTICLE Clin Endosc 2017;50:179-184 https://doi.org/10.5946/ce.2016.031 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant
More informationPapers. Abstract. Introduction. Methods. Jonathan J Deeks, Lesley A Smith, Matthew D Bradley
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Jonathan J Deeks, Lesley
More informationNonsteroidal anti-inflammatory drugs are among the
GASTROENTEROLOGY 2007;133:790 798 Risk of Peptic Ulcer Hospitalizations in Users of NSAIDs With Gastroprotective Cotherapy Versus Coxibs WAYNE A. RAY,*, CECILIA P. CHUNG, C. MICHAEL STEIN,, WALTER E. SMALLEY,,
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationComplementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib
Aliment Pharmacol Ther 2003; 17: 201 210. doi: 10.1046/j.0269-2813.2003.01407.x Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib R. H. HUNT*,
More informationUse of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know?
Rheumatology 2008;47:1342 1347 Advance Access publication 13 May 2008 doi:10.1093/rheumatology/ken123 Use of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know? U.
More informationMeasuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations
HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more
More informationNon-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract
Journal of Gastroenterology and Hepatology (2000) 15, G58 G68 WORKING PARTY REPORT: NSAID Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract JJY SUNG,* RI RUSSELL, 1 N YEOMANS,
More informationD DAVID PUBLISHING. 1. Introduction. Maher Mbarki 1, Helen Sklyarova 1, Krystyna Aksentiychuk 1, Ihor Tumak 2 and Eugene Sklyarov 1
Journal of Pharmacy and Pharmacology (2016) 32-36 doi: 10.17265/232-2150/2016.0.011 D DAVID PUBLISHING Plasma Levels of Leukotriene B and Prostaglandin E2 Correlation with Endoscopic Changes after NSAID
More informationOriginal Article. Abstract. Introduction
Original Article Frequency of NSAID Induced Peptic Ulcer Disease Saeed Hamid, Javed Yakoob, Wasim Jafri, Shanul Islam, Shahab Abid, Muhammad Islam Section of Gastroenterology, Department of Medicine, Aga
More informationGastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses
The Journal of International Medical Research 2002; 30: 301 308 Gastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses P RAMPAL 1, N MOORE 2, E VAN GANSE
More informationDrug Use Criteria: Cyclooxygenase-2 Inhibitors
Texas Vendor Program Use Criteria: Cyclooxygenase-2 Inhibitors Publication History Developed January 2002. Revised May 2016; October 2014; February 2013; December 2012; March 2011; January 2011; October
More informationPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin
Aliment Pharmacol Ther 2005; 22: 795 801. doi: 10.1111/j.1365-2036.2005.02649.x Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin N. D. YEOMANS*,
More informationClinical guideline Published: 13 June 2012 nice.org.uk/guidance/cg141
Acute upper gastrointestinal bleeding in over 16s: management Clinical guideline Published: June 2012 nice.org.uk/guidance/cg141 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationMonth/Year of Review: January 2012 Date of Last Review: February 2007
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:
More informationReview article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication
Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 66 70. Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication G. HOLTMANN* & C. W. HOWDEN
More informationAdherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries
J Gastroenterol (2013) 48:559 573 DOI 10.1007/s00535-013-0771-8 REVIEW Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries
More informationBritish Medical Journal. June 3, 2006;332: Patricia M Kearney, Colin Baigent, Jon Godwin, Heather Halls, Jonathan R Emberson, Carlo Patrono
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials 1 British Medical Journal June 3,
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationHaemoglobin decreases in NSAID users over time: an analysis of two large outcome trials
Alimentary Pharmacology and Therapeutics Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials J. L. Goldstein*, F. K. L. Chan, A. Lanas à, C. M. Wilcox, D. Peura, G.
More informationOver-the-counter (OTC) ibuprofen (200 mg), available
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:290 295 ORIGINAL ARTICLES A Randomized, Controlled Comparison of Ibuprofen at the Maximal Over-the-Counter Dose Compared With Prescription- Dose Celecoxib
More informationRecommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents
HOT TOPICS IN GASTROENTEROLOGY Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents Richard H Hunt MB FRCP FRCPC FACG
More informationClinical Investigations and Reports. Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Clinical Investigations and Reports Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Marvin A. Konstam, MD; Matthew R. Weir, MD; Alise Reicin, MD; Deborah Shapiro, DrPh; Rhoda
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationNSAID Regional Audit Group Presentation. Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston
NSAID Regional Audit Group Presentation Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston Thank you from the audit group for all who participated in the data
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationSurvey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly
Aliment Pharmacol Ther 1999; 13: 813±817. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly R. BOUTET, M. WILCOCK & I. MACKENZIE 1 Department of
More informationScottish Medicines Consortium
Scottish Medicines Consortium esomeprazole, 40mg vial of powder for solution for intravenous injection or infusion (Nexium I.V. ) No. (578/09) AstraZeneca 09 October 2009 The Scottish Medicines Consortium
More informationPREVENTING UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH HELICOBACTER PYLORI INFECTION
PREVENTING RECURRENT UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH HELICOBACTER PYLORI INFECTION WHO ARE TAKING LOW-DOSE ASPIRIN OR NAPROXEN FRANCIS K.L. CHAN, M.D., S.C. SYDNEY CHUNG, M.D., BING YEE
More informationManagement of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective
J Gastroenterol (2015) 50:626 637 DOI 10.1007/s00535-015-1038-3 REVIEW Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective Angel Lanas Carla J. Gargallo
More informationGASTRODUODENAL damage can be seen on endoscopy
Vol. 334 No. 22 TO PREVENT GASTRIC AND DUODENAL ULCERS CAUSED BY NSAIDS 43 FOR THE PREVENTION OF GASTRIC AND DUODENAL ULCERS CAUSED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS ALI S. TAHA, PH.D., NICHOLAS HUDSON,
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationA Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients
A Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients Christopher V. Chambers, MD, Walter L. Straus, MD, MPH, James J. Diamond, PhD, Lori A. Trapani,
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationCirculation. 2001;104: ; originally published online October 15, 2001; doi: /hc
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Marvin A. Konstam, Matthew R. Weir, Alise Reicin, Deborah Shapiro, Rhoda S. Sperling, Eliav Barr and Barry J. Gertz Circulation.
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationPREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS
PREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS LANSOPRAZOLE FOR THE PREVENTION OF RECURRENCES OF ULCER COMPLICATIONS FROM LONG-TERM LOW-DOSE ASPIRIN USE KAM CHUEN LAI, M.R.C.P., SHIU KUM LAM, M.D., KENT
More informationThe cardioprotective benefits of ... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin. Byron Cryer, MD
... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin Byron Cryer, MD Abstract The cardioprotective benefits of aspirin support the use of low-dose regimens for primary and secondary prevention of
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More information